Clinical Trial Update: Phase 2 Study of SAR302503 in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial of the investigational agent SAR302503 in patients with myelofibrosis has been completed, with results summarized in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hematopoietic Neoplasm | Phase 2 | Status: COMPLETED